Breast Cancer

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.

The cost of treating and managing breast cancer will rise two-and-a-half times by 2030 due to expected increases in young women being diagnosed with metastatic disease.

Tumor size and grade appeared to be associated with long-term survival in patients with estrogen receptor–positive/ERBB2-negative breast cancer who have undergone treatment with tamoxifen.

Myriad Genetics’ RiskScore offers personalized polygenic breast cancer risk assessment to undiagnosed women of all ancestries.

The combination of trilaciclib plus chemotherapy has been granted a fast track designation by the FDA for the treatment of locally advanced metastatic triple-negative breast cancer.

The FDA supported Athenex to continue developing oral paclitaxel and encequidar for patients with metastatic breast cancer.

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment.

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer.

Approximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.

Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status.

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.

Investigators aimed to determine if oncologic outcomes of patients in the real-world setting matched those of a pivotal clinical trial that led to the approval of eribulin mesylate in patients with metastatic breast cancer.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Reshma L. Mahtani, DO, about genomic testing to optimize treatment outcomes in HR-positive breast cancer.

The combination of alpelisib and fulvestrant maintained a tolerable safety profile for patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer who progressed after previous treatment with a CDK4/6 inhibitor.

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD about the current role of genomic testing in HR-positive breast cancer.

The long-term equivalence trial examined the rates of ipsilateral breast tumor recurrence for patients receiving electron intraoperative radiotherapy and whole-breast irradiation at 5-, 10-, and 15-year follow-up times.

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.

Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.

A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.

The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.

Insights into ongoing unmet needs in the individualized management of HR+ breast cancer and thoughts regarding future directions.